Trexquant Investment LP Reduces Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Trexquant Investment LP lowered its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 43.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 494,356 shares of the biotechnology company’s stock after selling 386,635 shares during the period. Trexquant Investment LP owned 0.24% of BioCryst Pharmaceuticals worth $3,718,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in BCRX. The Manufacturers Life Insurance Company raised its stake in BioCryst Pharmaceuticals by 40.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company’s stock worth $2,274,000 after acquiring an additional 86,571 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of BioCryst Pharmaceuticals by 1,058.1% in the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock valued at $3,127,000 after purchasing an additional 375,890 shares during the period. Teacher Retirement System of Texas raised its stake in shares of BioCryst Pharmaceuticals by 25.1% in the fourth quarter. Teacher Retirement System of Texas now owns 58,291 shares of the biotechnology company’s stock worth $438,000 after purchasing an additional 11,711 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of BioCryst Pharmaceuticals by 4.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company’s stock worth $14,890,000 after purchasing an additional 91,998 shares during the period. Finally, Geode Capital Management LLC boosted its position in BioCryst Pharmaceuticals by 2.7% in the third quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock valued at $36,776,000 after buying an additional 127,708 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Stock Down 6.8 %

Shares of BioCryst Pharmaceuticals stock opened at $6.83 on Monday. The firm has a market cap of $1.43 billion, a PE ratio of -11.20 and a beta of 1.84. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.03 and a twelve month high of $9.50. The business has a 50-day moving average price of $8.14 and a 200 day moving average price of $7.80.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. During the same period in the previous year, the business earned $0.28 EPS. BioCryst Pharmaceuticals’s quarterly revenue was up 40.8% on a year-over-year basis. On average, sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on BCRX. Royal Bank of Canada restated an “outperform” rating and set a $11.00 price objective (up from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. JMP Securities restated a “market outperform” rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Needham & Company LLC upped their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, January 13th. Wedbush began coverage on BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They set an “outperform” rating and a $15.00 price objective for the company. Finally, Evercore ISI upped their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $15.57.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.